Showing results (21-30 of 447) with videos related to
Sort By:
Pageof 45
Fortschritte Der Medizin|March 20, 1996
[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program]R P Byington, J W Jukema, J T Salonen, et al.Circulation|December 1, 1980
Clinical trials of platelet-active drugs in coronary heart disease: summary of design featuresC D Furberg, G S MayJournal of Hypertension|December 31, 1997
Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonistsB M Psaty, C D FurbergCirculation|June 1, 1983
Effect of beta-blocker therapy on recurrent nonfatal myocardial infarctionC D Furberg, R L BellCirculation|June 1, 1983
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experienceC D Furberg, R P ByingtonEuropean Heart Journal|February 1, 1988
The systolic hypertension in the elderly pilot program: methodological issuesC D Furberg, D M BlackHypertension (Dallas, Tex. : 1979)|May 1, 1989
The National Heart, Lung, and Blood Institute Workshop on antihypertensive drug treatment. The benefits, costs, and choices. Implications for researchC D Furberg, J A CutlerPreventive Medicine|July 1, 1985
Drug treatment trials in hypertension: a reviewJ A Cutler, C D FurbergCardiovascular Clinics|January 1, 1990
Systolic hypertension in the elderly: controlled or uncontrolledJ L Probstfield, C D FurbergCardiovascular Drugs and Therapy|September 1, 1996
Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspectiveC D Furberg, B M PsatyPageof 45